Patents Assigned to Crucell Holland B.V.
  • Binding molecules capable of neutralizing rabies virus and uses thereof
    Patent number: 9005624
    Abstract: Provided are binding molecules that specifically bind to rabies virus and are capable of neutralizing the virus. Further provided are nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from rabies virus. In certain embodiments, they can be used in the post-exposure prophylaxis of rabies.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: April 14, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Alexander Berthold Hendrik Bakker, Willem Egbert Marissen, Robert Arjen Kramer, Cornelis Adriaan De Kruif
  • Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
    Patent number: 8961978
    Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: February 24, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
  • Batches of recombinant adenovirus with altered terminal ends
    Patent number: 8932607
    Abstract: Described is a composition comprising a plurality of recombinant adenovirus particles, being a recombinant human adenovirus of serotype 5, 26, 34, 35, 48, 49 or 50, or a recombinant simian adenovirus, characterized in that the genomes of essentially all adenovirus particles in the composition comprise as the 5? terminal nucleotides the nucleotide sequence: CTATCTAT (nucleotides 1-8 of SEQ ID NO:7). Also described are methods to produce such compositions.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 13, 2015
    Assignee: Crucell Holland B.V.
    Inventors: Jerome H. H. V. Custers, Jort Vellinga
  • Acellular pertussis vaccine
    Patent number: 8916173
    Abstract: Described are acellular pertussis (aP) vaccine compositions comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 ?g per human dose.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: December 23, 2014
    Assignee: Crucell Holland B.V.
    Inventor: Jan Theunis Poolman
  • Host cell specific binding molecules capable of neutralizing viruses and uses thereof
    Patent number: 8911738
    Abstract: Provided are human binding molecules that specifically bind to a host cell protein and have virus neutralizing activity, nucleic acid molecules encoding such human binding molecules, compositions comprising the human binding molecules, and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of viral infections.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: December 16, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Mark Throsby, Cornelis A. de Kruif
  • Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
    Patent number: 8852595
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Grant
    Filed: October 10, 2013
    Date of Patent: October 7, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus H. J. Kwaks
  • Pneumatic alternating pressure membrane cell separation system
    Patent number: 8845902
    Abstract: Provided are filtration systems that can be referred to as Pneumatic Alternating Cell Separator (PACS), useful components thereof in the form of assemblies or kits of parts that can be used to build the system, and use of the system for filtering fluids, for instance, in cell culture perfusion systems comprising a filter-containing chamber, an expansion chamber and a gas flow controller.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: September 30, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Alain Pralong, Hans Ulrich Dellenbach
  • Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
    Patent number: 8834881
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: September 16, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus H. J. Kwaks
  • ACELLULAR PERTUSSIS VACCINE
    Publication number: 20140255446
    Abstract: Described are acellular pertussis (aP) vaccine compositions comprising Bordetella pertussis antigens pertussis toxoid (PT), filamentous hemagglutinin (FHA), and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), wherein FIM is present in an amount of 12-100 ?g per human dose.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 11, 2014
    Applicant: Crucell Holland B.V.
    Inventor: Jan Theunis POOLMAN
  • PRODUCTION OF POLIOVIRUS AT HIGH TITERS FOR VACCINE PRODUCTION
    Publication number: 20140242670
    Abstract: Described is a process for producing poliovirus, the process comprising: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and 150×106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.
    Type: Application
    Filed: May 12, 2014
    Publication date: August 28, 2014
    Applicant: Crucell Holland B.V.
    Inventor: John A. Lewis
  • Production of viruses, viral isolates and vaccines
    Patent number: 8802417
    Abstract: The present invention discloses methods for producing and/or propagating virus particles, such as influenza virus particles, that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle. The invention also provides a method for selective propagation of a set of virus particles, such as influenza virus particles present in an influenza isolate, which have an affinity for receptors comprising a specific glycosylation residue.
    Type: Grant
    Filed: July 16, 2007
    Date of Patent: August 12, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Giuseppe Marzio, Maria Grazia Pau, Dirk Jan Elbertus Opstelten, Alphonsus Gerardus Cornelis Maria Uytdehaag
  • Therapeutic vaccination against active Tuberculosis
    Patent number: 8771709
    Abstract: The invention provides a method for therapeutic treatment of a patient having active tuberculosis (TB), the method comprising: administering to the patient a recombinant adenovirus vector that comprises nucleic acid encoding the Ag85A, Ag85B and TB10.4 antigens of Mycobactium tuberculosis (Mtb). Advantageously, the method can be used to shorten conventional drug therapy for treating active TB.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: July 8, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Jerald Sadoff, Anisah Alyahya
  • VACCINE AGAINST RSV
    Publication number: 20140186391
    Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
    Type: Application
    Filed: March 22, 2013
    Publication date: July 3, 2014
    Applicant: CRUCELL HOLLAND B.V.
    Inventors: KATARINA RADOSEVIC, JEROME H. H. V. CUSTERS, JORT VELLINGA, MYRA N. WIDJOJOATMODJO
  • VACCINE AGAINST RSV
    Publication number: 20140147463
    Abstract: Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype 26 that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof.
    Type: Application
    Filed: March 22, 2013
    Publication date: May 29, 2014
    Applicant: CRUCELL HOLLAND B.V.
    Inventors: KATARINA RADOSEVIC, JEROME H. H. V. CUSTERS, JORT VELLINGA, MYRA N. WIDJOJOATMODJO
  • HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUSES OF PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUSES
    Publication number: 20140120113
    Abstract: The present disclosure relates to binding molecules, such as human monoclonal antibodies, that bind to an epitope in the stem region of hemagglutinin of influenza A viruses of phylogenetic group 1 and group 2, as well as influenza B viruses, and have a broad neutralizing activity against such influenza viruses. The disclosure provides nucleic acid molecules encoding the binding molecules, their sequences and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis and/or treatment of influenza A viruses of phylogenetic groups 1 and 2, as well as influenza B viruses.
    Type: Application
    Filed: July 12, 2012
    Publication date: May 1, 2014
    Applicant: Crucell Holland B.V.
    Inventors: Theodorus Hendrikus Jacobus Kwaks, David Adrianus Theodorus Maria Zuijdgeest, Ronald Vogels, Robert Heinz Edward Friesen
  • HUMAN BINDING MOLECULES HAVING KILLING ACTIVITY AGAINST ENTEROCOCCI
    Publication number: 20140099320
    Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the molecules. The molecules can be used, for example, in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.
    Type: Application
    Filed: December 10, 2013
    Publication date: April 10, 2014
    Applicant: Crucell Holland B.V.
    Inventors: Mark Throsby, Robert A. Kramer, Cornelis A. de Kruif
  • Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof
    Patent number: 8691223
    Abstract: Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: April 8, 2014
    Assignee: Crucell Holland B.V.
    Inventors: Edward Norbert Van Den Brink, Cornelis Adriaan De Kruif, Mark Throsby
  • BATCHES OF RECOMBINANT ADENOVIRUS WITH ALTERED TERMINAL ENDS
    Publication number: 20140073032
    Abstract: Described is a composition comprising a plurality of recombinant adenovirus particles, being a recombinant human adenovirus of serotype 5, 26, 34, 35, 48, 49 or 50, or a recombinant simian adenovirus, characterized in that the genomes of essentially all adenovirus particles in the composition comprise as the 5? terminal nucleotides the nucleotide sequence: CTATCTAT (nucleotides 1-8 of SEQ ID NO:7). Also described are methods to produce such compositions.
    Type: Application
    Filed: March 11, 2013
    Publication date: March 13, 2014
    Applicant: Crucell Holland B.V.
    Inventors: Jerome H. H. V. Custers, Jort Vellinga
  • HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING INFLUENZA B VIRUSES AND USES THEREOF
    Publication number: 20140065165
    Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.
    Type: Application
    Filed: October 10, 2013
    Publication date: March 6, 2014
    Applicant: Crucell Holland B.V.
    Inventors: Ronald Vogels, Theodorus H. J. Kwaks
  • HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA VIRUS H5N1 AND USES THEREOF
    Publication number: 20140065156
    Abstract: Described are binding molecules such as human monoclonal antibodies that bind to influenza virus H5N1 and have neutralizing activity against influenza virus H5N1. Also described are nucleic acid molecules encoding the antibodies, and compositions comprising the antibodies and methods of identifying or producing the antibodies. The antibodies can be used in the diagnosis, prophylaxis, and/or treatment of an influenza virus H5N1 infection. In certain embodiments, the antibodies provide cross-subtype protection in vivo, such that infections with H5, H2, H6, H9, and H1-based influenza subtypes can be prevented and/or treated.
    Type: Application
    Filed: October 1, 2013
    Publication date: March 6, 2014
    Applicant: Crucell Holland B.V.
    Inventors: Edward N. van den Brink, Cornelis A. de Kruif, Mark Throsby